Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 6/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 4/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 3/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21596857 | 0.79 | HTR3A (0.47) | LTB4RMAOBMAOAHTR3A | |
| SCHEMBL6957651 | 0.77 | LTB4R (0.47) | LTB4RMAOBHTR3A | |
| SCHEMBL15145315 | 0.77 | LTB4R (0.49) | LTB4RMAOBMAOA | |
| SCHEMBL18639866 | 0.75 | PARP15 (0.51) | PARP10PARP15MAOBMAOAPARP2 | |
| SCHEMBL8305850 | 0.74 | MAOB (0.52) | MAOBMAOAACHE | |
| SCHEMBL6952286 | 0.73 | CLK1 (0.50) | LTB4RMAOBMAOAHTR3A | |
| SCHEMBL18302407 | 0.72 | HTR3A (0.48) | HTR3AACHEKCNH2 | |
| SCHEMBL23117306 | 0.71 | PARP15 (0.44) | PARP10PARP15MAOBMAOACYP11B1 | |
| SCHEMBL16450868 | 0.71 | LTB4R (0.45) | LTB4RMAOBMAOA | |
| SCHEMBL18640109 | 0.70 | PARP10 (0.53) | PARP10PARP15MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| CN-112334466-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| WO-2019243491-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153710-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | PARP10 2739/4885PARP15 2752/4885LTB4R 2470/4885 |
| US-20200039945-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | PARP10 2743/4885PARP15 2752/4885LTB4R 2469/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | PARP10 2574/4885PARP15 2801/4885LTB4R 4208/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | PARP10 2743/4885PARP15 2752/4885LTB4R 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.